LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.
| 99200 | |
| 99000 | |
| - | |
| 100700 | |
| 97000 | |
| 43600-143600 | |
| 3 646 373 M | |
| 36 427 K | |
| 76 216 M | |
| 308.8293 | |
| 0.974 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
- Samsung Biologics to develop and manufacture antibody for ADC candidate - Latest deal comes as Samsung Biologics is on track to complete construction of an ADC facility this year INCHEON, South Ko...
SOTIO Biotech SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumors Preclinical efficacy and tolerability studies of SOT106 show promis...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
